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“There is a theory which states that if ever anyone discovers exactly what the Universe is for 
and why it is here, it will instantly disappear and be replaced by something even more bizarre 
and inexplicable. 
There is another theory mentioned, which states that this has already happened” 
 
Douglas Adams  
  
To Molly and Ellis
  
ABSTRACT 
Allergy is a disease affecting around 30% of the population worldwide, causing extensive suffering 
for individual patients and constituting a significant socioeconomic burden to society. The 
immunological reaction in allergy causes symptoms in the range from mild itching and runny nose to 
systemic death threatening states. One common cause of allergy is pets, such as dog and horse. 
Today’s diagnostics of pet allergy is frequently based on extract from dander or hair, however extracts 
may vary in content of allergens. The only curative treatment is allergen specific immunotherapy 
(SIT), routinely performed by injections with allergen extracts. For both diagnostics and treatment, the 
content of allergen component in the extracts is vital. The application of DNA technology has opened 
opportunities to produce allergens in pure form and at good yield, making the allergen components 
available for both diagnostics and SIT. Further improvement of SIT could be achieved by the use of 
adjuvants able to skew the allergic immune response to a non-allergic response. Currently, the 
adjuvant alum is used in SIT. New adjuvants are needed that more efficiently stimulate regulatory or 
Th1 type responses. 
The aim of this thesis was to identify and analyze new sources of pet allergens, to identify new 
allergen components from horse and dog, and to investigate mechanisms and clinical safety/efficacy 
of a novel adjuvant candidate based on chitosan, which will possibly be suitable for future use in SIT, 
as well as for other vaccine applications. 
In paper I of this thesis we investigated dog saliva as a possible allergen source, and if today’s 
diagnostic extract could be improved by using saliva. We found that some individuals with negative 
IgE test to dog dander have IgE to dog saliva, and that the IgE binding is biologically relevant, as dog 
saliva could activate basophil degranulation. Using immuno-proteomic analyses, four potential IgE 
binding proteins not previously described as allergens were identified. 
In paper II we present a thorough analysis of horse allergen components. We identified three novel 
full-length IgE binding proteins and evaluated the prevalence of IgE reactivity among 100 sera from 
horse sensitized individuals. All three novel allergens belong to protein families from which allergens 
from dog, cat or cow have previously been described. The prevalence of sensitization to the new 
allergens ranged between 34 and 66% and together with three additional known horse allergens all 
100 sensitized individuals could be detected.  
Paper III investigated the adjuvant candidate ViscoGel, composed of chitosan based viscoelastic 
particles. ViscoGel’s ability to be phagocytosed by, and activate antigen presenting cells was studied 
in vitro. The antigen presenting cells were able to take up the chitosan particles of 10 and 200µm size, 
and to stimulate the release of IL-1β in a caspase-1 independent manner.  
Paper IV describes a clinical phase I/IIa trial evaluating safety of ViscoGel alone and in combination 
with the model vaccine Act-HIB, and efficacy as an adjuvant for Act-HIB. ViscoGel was well 
tolerated when injected intramuscularly. No adjuvant effect was observed on the antibody response to 
Act-HIB, but the IFN response was affected, suggesting that ViscoGel may promote a Th1 type of 
response. 
To conclude, the results presented in this thesis have the potential to improve diagnostics of allergy to 
dog and horse. Moreover, a new potential adjuvant was shown to be safe and exhibited immunological 
properties that may be favorable for use in SIT. 
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
The human body has been fighting different diseases and harmful pathogens in our environment 
throughout evolution. These efforts, on individual basis, are made to maintain the integrity of our 
bodies intact, preventing cells from dying and preserving nutrients for ourselves (1). This has driven 
us into evolving an immune system with a wide range of mechanism to both escape and attack the 
potentially harmful agents. Usually this is the classical way to consider what function the immune 
system has, attacking foreign molecules that can potentially harm us and neglect own-produced 
molecules necessary for survival. Somewhat contradicting to this picture to discriminate between 
self and non-self, is the immune system’s ability to recognize infected cells or even tumor cells (2). 
Therefore the route by which activation of the immune system occurs is complex, with different 
results dependent on the activation signal. 
To protect against pathogens, the human body is covered with a protective barrier, the skin. The 
skin’s epithelial layer is hard to penetrate for any bacteria or virus. It is also covered by non-
pathogenic microorganisms, a microbiota that will compete with potential pathogens for both space 
and nutrients. The skin is coated with proteins and anti-microbial peptides, targeting bacteria, 
adding to the outer defense against pathogens (3, 4). The outer layer of the skin is just the first line 
of defense that a pathogen has to overcome to infect a human. 
The multifaceted world of proteins and cells that fight against our enemies is usually divided into to 
two specific systems, innate immunity and adaptive immunity (5). The innate system is the quick 
responder that we are born with, it is inherited and highly conserved, reacting towards  conserved 
recognition patterns derived from pathogens (6). The adaptive immunity is on the other hand 
constantly evolving, modulating its receptors for pathogen recognition. Therefore it is slower in the 
start, however vastly more specific and with the ability to undergo expansion. Not only does it react 
but it is also capable of creating a memory of the pathogen, making the next encounter of the same 
pathogen easier to react toward, both faster and more specific than the initial response.  
1.2 ANATOMY OF THE IMMUNE SYSTEM 
To give a perspective of the important anatomical structures and organs of the immune system, one 
should first consider the barriers pathogens need to penetrate. That is the skin—or in Latin 
epidermis— for the exterior part of the body, and the interior is the mucus membrane—in Latin the 
mucosa. These barriers are covered by physical obstacles preventing penetration, such as dead cells, 
bacteria and mucus. Epithelial cells are not immunological cells per se, but are still important 
both as a barrier, and relevant for this thesis, as a mediator of signaling in inflammation and 
disease (7). The barriers, which the epithelium make up, need to signal to immune cells 
which state it is in and induce and facilitate migration of cells into the tissue, so they have a 
vital role in the immunological interaction, and also play a role in skewing the response (8). 
Other structures important for the immune system are the bone marrow, from where the stem cells 
of the blood system originate. The process when blood cells mature from a stem cell is called the 
hematopoiesis, and is the origin of most immunological cells, with a few exceptions. The bone 
marrow together with the thymus make up what is called the primary lymphoid organs. In the 
thymus a sub-set of immune cells undergo negative selection based on their recognition of self- 
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molecules, to prevent reactions to own tissue. Secondary lymphoid organs are the lymph node and 
the spleen, where some immunological cells are activated, based on their recognition of foreign 
molecules, and where the communication between the innate and the adaptive immune system 
occurs. 
1.3 CELLS OF THE IMMUNE SYSTEM 
Most cells that belong to the immune system are cells stemming from a common pluripotent stem 
cell that resides in the bone marrow, but there are exceptions and still cells with unknown 
progenitors and unclear anatomical origin (7).  The bone marrow derived cells migrate into the 
bloodstream, where they are patrolling and ready to migrate into stress- or danger-signaling tissue. 
Dependent on their site of activation and maturation they are divided into myeloid or lymphoid 
cells, where the myeloid cells belong to  the innate immunity and lymphoid cells belong to the 
adaptive, but there are exceptions from this distinction of cells as well. To identify and discriminate 
between different cells a system called cluster of differentiation (CD) has been developed to classify 
surface expressed molecules (9) 
.  
Figur 1 Granulocytes From left to right: neutrophil, basophil and eosinophil. 
 
Figur 2 ANTIGEN PRESENTING CELLS AND LYMPHOCYTES From left to right: monocyte, macrophage, DC and 
lymphocyte. 
1.3.1 Granulocytes 
Three subtypes of cells packed with vesicles, filled with effector molecules and mediators, named 
after their granules are identified granulocytes (10). They are colored differently when stained with 
hematoxylin and eosinophilic stain, and the circulating subclasses are named after their staining: 
basophils, neutrophils and eosinophils (figure 1).  
1.3.1.1 Neutrophils 
Neutrophils are abundant in the blood and infiltrate inflamed or damaged tissue within just a few 
hours (11). They are characterized by a polymorphic nucleus and are phagocyting cells that can 
release neutrophil extracellular trap, to trap pathogens. Neutrophils also have the ability to migrate 
to lymph node upon activation and function as a hybrid between dendritic cell (DC) and neutrophil 
(12, 13).  
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1.3.1.2 Basophils  
Basophils are rare cells, only around 1% of the granulocytes are basophils. However, they are 
important cells of allergic reaction (14). Basophils have the ability upon cross-linking of IgE bound 
to the high affinity receptor of IgE (FcRI) to release histamine and other mediators, Together with 
mast cells they are key players in the early phase of the allergic reaction. Since basophils are present 
in the blood, they may be used in the clinical evaluation of allergic reactions (15, 16). Basophils and 
mast cells can release the allergy associated mediator histamine, proteases, cytokines and other 
inflammatory mediators.  
1.3.1.3 Eosinophils 
Eosinophils, like neutrophils, are rapidly recruited to inflammatory sites (17). They have been 
described to play a role in the defense against parasites but also in the development of asthma (18). 
The eosinophil, as the other granulocytes, release their granulae content upon activation. Eosinophils 
release inflammatory mediators and proteins that propagates and modulates the immunological 
reaction. 
1.3.1.4 Mast cells 
Mast cells are tissue resident cells, which  are major players in allergic disease (19). They 
share many features of the basophil, including expression of the high affinity IgE receptor, 
ability to release histamine and other mediators upon allergen mediated cross-linking of IgE 
receptors and activation of other immunological cells (19).  
1.3.2  Antigen presenting cells 
The ability to take up extracellular molecules and present these to the adaptive immune system is the 
function of antigen presenting cells (figure 2)(APCs)(20). These cells include DCs and macrophages, 
which belong to the innate immunological cells, and the B-cells (the latter will be addressed under the 
description of adaptive immune cells). Common for the APCs are their ability to present foreign 
peptides. However, new insights make this classical nomenclature disputable, with reports of 
granulocytes acting as APCs (13, 20).  Therefore one discriminate between professional, i.e. B-cells, 
DCs and macrophages, and atypical, i.e. all other cells with unclear ability to induce T lymphocytes. 
1.3.2.1 Antigen presentation.  
There are two classes of  the major histocompatibility complex (MHC) molecules—class I and II— 
which are encoded by distinct clusters of genes (21). They present peptide fragment from proteins, 
either from cytosolic derived proteins (MHC I), or exogenous proteins found in intracellular 
vesicles (MHC II) (22). MHC I molecules on APCs have however also been demonstrated to 
present peptides derived from proteins taken up by the cell, a process called cross-presentation (23). 
They become loaded on the MHC I on professional APCs and are then transported to the cell-
surface with the peptide attached. The MCH-peptide complex is then presented to the T-cell via the 
T-cell receptor (TCR). Professional APCs have a special role in antigen presentation, they have the 
ability to activate naive T-cells via co-stimulatory molecules on their surface. In humans, the genes 
encoding MHC I and II are called human leukocyte antigen (HLA), the A, B and C type encodes the 
MHC I and the HLA-DR, DQ and DR encodes the MHC II (23).MHC I presents peptides of 8-9 
amino acids in length and MHC II peptides of15-24 amino acids (22).  
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1.3.2.2 Monocytes 
 
Monocytes are mononuclear cells patrolling the bloodstream. They migrate to sites of inflammation 
and infection, via blood vessels. There the monocytes develop into macrophages or DCs dependent 
on the signaling from the surrounding (24).  
1.3.2.3 Macrophages  
 
Macrophages are professional phagocytizing cells. There are two distinct macrophage subtypes, M1 
and M2, distinguished by their ability to produce IFN and nitric oxide (M1), or to promote tissue 
repair and produce interleukin (IL)-6 (M2) (25). Macrophages belong to the professional APCs. 
They express pathogen recognition receptors like Nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLR), and are key cells in microbial defense. Moreover, as APCs they have 
the ability to present antigen to T-cells via MHC class II as well as MHC I. Macrophages could be 
derived from monocytes or be tissue resident (24).  
1.3.2.4 Dendritic cells 
Dendritic cells have a specific role in the induction of the adaptive response(26). Upon activation of 
DCs, usually due to infection or inflammation, the cells will migrate to the lymph node and present 
peptides from the periphery to antigen specific T lymphocytes and activate them. Dendritic cells 
both express MHC class I and II and upon activation they expresses co-stimulatory molecules, 
making T-cell activation and priming of an adaptive response possible (27). In addition, molecules 
secreted from the DCs contribute to the shaping of the immune response by inducing functionally 
distinct effector cells (27). 
1.3.3 Lymphocytes 
Cells found in the lymph system are referred to as lymphocytes and are classified dependent of 
function (figure 2)(7). The lymphocytes described in this thesis are the cells of the adaptive immunity, 
however some subclasses of lymphocytes or lymphoid cells belong to the innate immunity, e.g. NK 
cells, NKT cells and innate lymphoid cells (7). 
1.3.3.1 T-cells 
T lymphocytes are named after the location where they undergo selection of their antigen binding 
capacity, namely the thymus (7). They belong to the adaptive immunity and can be divided into 
several different subclasses. T-cells are identified via the cell-surface protein CD3, an accessory 
protein acting as a co-receptor to the TCR, responsible for antigen recognition. The TCR undergoes 
selection in the thymus based on the ability to bind MHC molecules, were T-cells with TCR that do 
not bind or binds to strong is sorted out and undergo apoptosis (28). The T-cells that pass this 
selection enter the circulation and start patrolling the periphery until they encounter an APC that 
presents an a peptide in the context of an MHC which is recognized by the T cell together with a co-
stimulatory signal (28, 29). Subclasses of T-cells include the CD8 positive T-cells, or cytotoxic T-cells 
(CTL), which are specialized in killing cells. The CTLs present antigen on MHC class I and killing is 
mediated by grancymes or FAS ligand interaction with the MHCI presenting cells (30). CD4 positive 
cells, or T helper cells (Th), are promoting humoral immune responses. There are several Th 
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subclasses, the first two identified were Th1 and Th2 (31). The subclasses are identified by their 
cytokine signatures or expression of transcription factors; Th1 cells release IFN and expresses T-bet 
and Th2 cells releases IL-4, IL-5 and IL-13 and expresses GATA3 (32, 33). Later, a number of Th 
subclasses have been described, the most established being Th17, expressing RORt, and T regulatory 
(Treg) cells. Th17 cells secrete the signature cytokine IL-17, while Treg cells may secrete immune 
regulatory cytokines such as IL-10 and TGF-β and is usually identified by the transcription factor 
FOXP3 (31, 34-36). Each Th subclass is associated with different immunological responses; Th1 
mediate responses against intracellular pathogens, Th2 against extracellular parasites and Th17 against 
extracellular bacteria. The function of Tregs is to down-regulate immune responses or to induce 
tolerance.  
1.3.3.2 B-cells  
B-cells are named after the organ where the cells were first identified — the bursa of birds— a 
lymphoid organ localized in close proximity to the gut of birds (37). However the name of the cells 
can also be applied on their origin in mammals, the bone-marrow. B cells belong to the adaptive 
immunity (20). They start their development in the bone marrow where the B cell undergo selection 
based on the rearrangement of immunoglobulin (Ig) genes (38). The B-cells then becomes activated 
once the cell has taken up foreign protein via its cell-surface bound Ig, internalized it, degraded and 
presented it on MHC II to an activated Th-cell (7, 29, 39). This leads to induction of the B-cell to 
produce soluble Ig, followed by clonal expansion, Ig sub-class switching and establishing  
immunological memory (39). However, B-cells can start producing Igs independent of T-cells, a 
process where repetitive epitopes, such as carbohydrates, binds and activates the B-cell without T-
cell help (40). In addition to their role as antibody producers, B-cells can also act as professional 
APCs (20) 
1.3.3.3 Immunoglobulin 
Immunoglobulin—or antibodies— are proteins produced by B-cells, specialized in binding 
antigens. The ability of antibodies to generate immunity against pathogens and toxins was 
discovered in the late 1800. There are five different Ig subclasses found in humans: IgA, IgD, IgG, 
IgE and IgM. Each Ig subclass has a specialized function (37, 41). The structure, with two heavy 
chains and two light chains, can be visualized as the shape of a Y (41). The antibodies consist of a 
variable region at the “tip” of the Y, which binds to the antigen, and a constant region, with the 
ability to bind to cellular antibody Fc receptors dependent on the class of the constant region (41). 
For example, and relevant for this thesis, the IgE antibody subclass  binds the high affinity 
receptor FcRI and the low-affinity receptor FcRII (16). The high affinity receptor is 
expressed mainly on mast cells and on basophils, and the low affinity receptor is expressed , 
among others, by B-cells (16). One could view this cellular binding of Ig:s to Fc-receptors as 
a way of the adaptive immunity to transfer its antigen recognition to specialized effector cells. 
1.4 IMMUNOLOGICAL RECEPTORS OF ACTIVATION. 
To activate cells to target pathogens or in response to stress, cells display and produce a broad 
variety of molecular detectors (42). These receptors, or pathogen recognition receptors (PRR), are 
activated by different classes of ligands. They may be further divided into different subclasses, 
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called pathogen associated molecular patterns (PAMP) or Damage-associated molecular pattern 
molecules (DAMP), dependent of the source of activation.  
Table 1 Toll-like receptors the ten toll-like receptors described in humans. 
  Toll-like receptors     
  Pathogen Ligands Endogenous Ligands Cellular location 
TLR1/2 Triacyl lipopeptides - Cell membrane 
TLR2/6 Diacyl lipopeptides, zymosan HSP Cell membrane 
TLR3 dsRNA mRNA Endosome 
TLR4 LPS HSP Cell membrane 
TLR5 Flagelin - Cell membrane 
TLR7 ssRNA immune complexes Endosome 
TLR8 ssRNA immune complexes Endosome 
TLR9 CpG-DNA immune complexes Endosome 
TLR10 - - - 
1.4.1 Toll-like receptors. 
Among the well-studied innate receptors are Toll-like receptors (TLR) (German for funny-looking 
receptors) that are characterized by an N-terminal leucine rich repeats (LRR) domain and a 
cytoplasmic Toll/IL-1 receptor (TIR)-domain (43-48). These receptors all react towards different 
types of ligands. Ten different TLRs have been identified in humans (Table 1)(covered in this 
thesis) (48).  TLRs signal via the myeloid differentiation primary response gene 88 (MyD88) or 
TIR-domain-containing adapter inducing interferon (IFN)-Β (TRIF) signaling pathway. They can be 
divided into different clusters dependent on their ligands: some react towards lipids, other against 
bacteria or virus derived molecules. TLR1 and TLR 6 form a dimer with TLR2, and are cell 
membrane bound receptors (figure 3)(48). The TLR1/2 dimer reacts towards lipoproteins, but 
TLR2/6 are broader in activation, with both recognition of microbial ligands such as lipopeptides 
and zymosan, but also have endogenous activators such as heat shock proteins (HSP) (47). When 
bound to their ligands, these TLRs activate MyD88 downstream (figure 3). TLR3 is not found on 
the cell surface, but expressed on endosomes (figure 4) and does not activate MyD88. Instead it 
activates the TRIF pathway, in response to its virus derived ligand dsRNA (6). TLR4 was 
discovered via a spontaneous mutation in the mouse gene lps, making these mice tolerating high 
levels of endotoxins (49). TLR4 recognizes lipopolysaccharide (LPS) in combination with the 
protein myeloid differentiating factor 2 (MD2) (50, 51). TLR4 is the only TLR that activates both 
the MyD88 pathway and the TRIF pathway and can be internalized, therefore it works both as a 
surface-receptor and an endosome receptor (figure 3). TLR5 is activated by bacteria-derived 
flagelin and is also expressed on the cell surface and activates the MyD88 pathway (figure 3) (6). 
TLR7 and 9 resides in the endosome, and are activated by virus derived ligands, such as DNA and 
ssRNA (6, 52). In common for all of them is that they activate the transcription factor Nuclear 
factor kappa light-chain enhancer of activated B-cells (NFκB). All TLRs are not expressed by 
all immune cells, some seem to be restricted in their cellular expression (42). After detection of 
danger signals from a receptor via PAMP or DAMP there is a cascade of downstream signals, and 
dependent of receptors involved and the type of ligand, a signaling pathway is activated (42). 
Signaling via membrane-bound TLRs gives rise to different signaling cascades depending on which 
TLR is activated. Simplified one could describe the extracellular exposed TLRs as MyD88 
dependent activators of the nuclear transcription factor NFκB, where the activation of NFκB leads 
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to induction of different inflammatory cytokines (46). On the other hand endosomal TLRs signal via 
TRIF and MyD88 and activates interferon regulatory factors (IRF) and NFκB. Activation of the 
MyD88 pathway is essentially results in recruitment of IL-1-receptor-associated kinases (IRAK) 
and downstream the mitogen associated protein kinase (MAPK) and NFκB. The recruited IRAK 
also, via NFκB essential modifier, removes an inhibitor of NFκB (IκB) (53, 54).  Activated NFκB 
stimulates production of several cytokines, such as IL-12p40 and IL-6. The TRIF pathway does not 
only activate the NFκB pathway and MAPK, which is activated via TNF receptor associated factor 
(TRAF) 6 and TRADD, but also activates the TRAF3 signaling to IRF3, leading to IFN -β 
transcription (42, 55). TLR 7 and 9, the endosomal MyD88-associated TLRs, activates the 
production of antiviral type I IFN via IRF7. IRF7 is expressed constantly in plasmacytoid DCs, and 
also IRF5 can be activated via TLR7 and TLR9 (42). 
  
 
 
 
 
 
 
 
 
 
 
 
 
1.4.2 Non-TLR receptors of innate immunity 
Other receptors of the immune system are C-type lectin receptors (CLR) and NLR. NLR play a 
pivotal role in activation of the immune complex known as the inflammasome, driving the 
production of IL-1β and IL-18 (56). CLRs have been demonstrated to be activated after fungal 
infections, and several members of this protein family have been described (57, 58). However, also 
immunity against other pathogens than fungi has been described for these receptors. The signaling 
Figure 3TLRs on the cell surface. The cell surface bound TLRs are 
specialized in recognition of microbial derived PAMPs, such as 
flaggelin, LPS and Lipopeptide. These ligands activate a signaling 
cascade, starting from the adopter-protein TIRAP, via MyD88 to NFB 
activation. This results in transcription of inflammatory cytokines. 
 
Figure 4 The TRIF signaling endosomal TLRs. Endosomal 
TLR4 activated by its ligand LPS signals via the adaptor 
molecules TRAM and TRIF, in contrast to TLR3, which is 
activated by dsRNA and signals only via TRIF. However both 
give rise to activated NFB inducing inflammatory cytokines, 
but   IRF3 that give rise to type 1 IFNs 
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of CLR is via immune receptor tyrosine activation (ITAM)-like motifs or ITAM-associated 
proteins.  
1.4.3 Caspases and the inflammasome 
Caspases constitute a protein family named after their essential function and composition, a cysteine 
protease with the ability to cleave proteins after aspartic acid residues (56, 59). The caspases have 
various functions, either inflammatory or apoptotic. Twelve caspases have been identified in 
humans. Most well studied for immunologists are the caspase-1, with the pro-domain caspase 
activation and recruitment domain (CARD) – all inflammatory caspases have this domain. Five 
different protein complexes have been shown to activate caspase 1. These complexes are denoted 
inflammasome, and their activation pathways involve PAMP or DAMP signaling via different 
receptors. For example, the NOD, LRR and pyrin domain- containing -inflammasome is activated 
by anthrax toxin and the NOD-like receptor and  pyrin domain containing protein 3 (NLRP3) 
inflammasome is activated via several DAMPs. Toxins from Salmonella bacteria are detected by 
the neuronal apoptosis inhibitory proteins (NAIP) and form a complex with NOD-LRR and CARD 
containing protein 4 (NLRC4) and is therefore named NAIP-NLRC4 inflammasome. One identified 
caspase that senses DNA has been named absent in melanoma (AIM) 2. The last of the caspase-1 
activators described in the literature is the Pyrin inflammasome, activated via bacterial toxins. The 
effect of Caspase-1 is that it cleaves pro-IL-1β and pro-IL-18, and the protein Gasdermin D, leading 
to the release of IL-1β and IL-18 (60, 61). Activation of Caspase-1 can occur via the TLR4 pathway 
or through the non-canonical pathway. Caspase-11 can be activated via LPS in the cytoplasm, and 
thereafter activates the NLRP3 inflammasome, and this pathway is called the non-canonical 
pathway (56).  
1.5 ALLERGY 
Allergy is a hypersensitivity reaction of the immune system towards foreign proteins or 
glycoproteins.  The reported prevalence of any sensitization is reported to be around 30 %, and 
seems to increase worldwide (62, 63). In this thesis allergy refers to IgE mediated allergy. This is 
the most common form of allergy, although allergic reactions may also be non-IgE mediated (64). 
The molecules that the immune system reacts towards are referred to as allergens (64). Individuals 
prone to produce IgE, due to a personal or familiar predisposition, are referred to as atopic. Clinical 
manifestation of the immunological reaction of allergy is commonly rhinitis, asthma, skin 
inflammation or rashes. Systemic reactions occur more rarely and may in worst-case lead to life 
threatening anaphylaxis (65). The incidence of allergy worldwide seems to increase (63). One 
proposed reason is the “hygiene hypothesis”. In a simplified way it can be explained by a reduction 
of Th1 responses against microbes due to less burden of microbes in a modern clean, i.e. hygienic, 
environment.  Thus the Th2 prone immune status of the infant will not deviate to a Th1 promoting 
status in the absence of microbial challenge, resulting in an increased risk of allergic disease (66). 
Also lack of regulatory cells and cytokines, like Tregs and  IL-10, in a highly hygienic environment  
is a proposed mechanism of the increased incidence of allergic diseases (66). 
1.5.1 Allergens 
Molecules that cause allergic reaction are referred to as allergens. Allergens are usually proteins, 
but in rare cases the IgE binding capacity is the sugar residue on glycoproteins. Allergens are 
suggested to be divided into three subclasses; I) indoor allergens II) pollen allergens and III) plant 
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and animal food allergens (67). The reason why some proteins are targeted by the immune system 
with a Th2 type response associated with allergy in unclear. However, several of the indoor 
allergens derived from house dust mite have been reported to promote Th2 cytokines, or trigger 
TLR4 activation and induce NFκB of B-cells (67-69). The major cat allergen Fel d 1 and the dog 
allergen Can f 6 have also been reported to activate TLR4 in vitro (70). Cross-reactions, i.e. IgE 
binding similar epitopes on different allergens or homologous protein might explain why some 
allergens are IgE binding, but also epitope spreading might explain some sensitization. However a 
primary sensitization is needed even if this effect could explain why some proteins family have a 
tendency of being targeted by the immune system (71-73). 
1.5.2 Sensitization phase 
The first encounter of an allergen, does not lead to an allergic reaction. First the immune system 
needs to promote the B-cells into production of antigen specific IgE. This happens upon 
presentation of allergen to naïve T-cells, which promote B-cells (figure 5) (74). First the allergens 
are taken up in the periphery by DCs, which migrates to the lymph node, where the allergen derived 
peptide can be presented on MHC II to the TCR of naïve T-cells. Theses T-cells differentiates into 
Th2 cells by IL-4 secreted from the DCs. Exactly how this IL-4 secreting DCs are induced is not 
fully understood, but one possible explanation is that it might be due to Th2-promoting adjuvant 
properties of the allergen, and as described above (75, 76). Also other molecules associated to the 
allergen, such as LPS, could work as an adjuvant and influence the type of response (77). Key 
molecules in the activation of Th2-responses have been reported to be IL-25, IL-33 and TSPL, 
molecules released from stressed or damaged epithelium (8, 68, 73, 78, 79). The Th2 cell then 
activates and promotes the B-cell to undergo class-switch, i.e. change the subclass of antibody 
production to IgE. 
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Figure 5 Sensitization phase DCs take up the antigen in the periphery, and become activated, IL-4 producing via IL-33, IL-
25 and TSPL secreted from tissue. The activated DC migrate to lymph node, and presents the allergen derived MHC II bound 
peptide to naïve T-cell and activates them via the TCR-MHC interaction and co-stimulatory signaling. The IL-4 producing 
DC skews the response towards Th2. Th2 cells starts secreting IL-4 and IL-13, and when encountering B-cells presenting the 
same peptide as before, the T-cell promotes the B-cell to start producing allergen specific IgE. 
1.5.3 Effector phase- the immediate reaction 
When a sensitized individual, i.e. an individual with pre-formed allergen specific IgE, encounters 
the allergen an immediate phase reaction occur (74). If the allergen binds to two IgE, that are bound 
to FcRI of tissue resident mast cell or circulating basophils, a cross-linking could occur that causes 
a cell activation (16). This activation leads to release mediators stored in pre-formed vesicles. The 
content of the vesicles are different immunological mediators (bioactive amines and lipid 
mediators), enzymes and cytokines. Histamine is one of the key inflammatory mediators, causing 
bronchoconstriction via smooth muscle constriction, increasing vascular permeability and 
vasodilatation via its effect on epithelial cells (80). Histamine release, together with other 
mediators, therefore affects lung function and blood pressure, making breathing more difficult and 
blood-pressure to drop, as well as causing local edema. The mast cells are also induced to produce 
and release cytokines, for example IL-4, driving the Th2 skewing even more, as well as other pro-
inflammatory cytokines such as IL-5 (81, 82). These reactions occur within minutes after the 
allergen encounter. The increased permeability and induction of inflammation is causing classical 
symptoms associated with allergy such as rhinitis, watery  and itching eyes, the previous mentioned 
reduction in airway function, and local swelling and edema (16). The molecules released from the 
mast cells and basophils also works as chemo attractants for other immunological relevant cells. 
1.5.4 Effector phase- the late phase reaction 
The late phase reaction occurs after several hours, when the cells recruited to the affected 
tissue start to exert their effect (74). Here the role of allergen specific Th2 cells is of great 
importance, for example by secretion of IL-5 that attracts eosinophils (83). Thus not only T 
lymphocytes infiltrate the tissue, but also eosinophils and to some extent neutrophils. This 
recruitment increases the inflammatory response (82). Activated eosinophils release 
inflammatory mediators, propagating and elevating the inflammatory response. Other factors 
that might play a role in the late phase reaction is FcRI-IgE dependent antigen presentation 
(84). The late phase reaction has been regarded as a cause of the remodeling of the airways, 
leading to chronic and persistent problems (85).  
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1.5.5 Chronic phase 
The chronic phase of allergic inflammation involves the remodeling of the tissue after 
persistent allergic inflammation (86). For example, in the case of asthma, an increase of 
mucus producing cells can be observed in the bronchial tract, and inflammation, fibrous 
tissue and areas of epithelial damage (87). This phase might even increase the risk of 
respiratory virus infections, due to reduction in the IFN response (87).  
1.5.6 Allergy to pets 
Allergic reactions or sensitization to allergens from furry animals are very common. As an example, 
in a study made in northern Sweden 2009, the rate of sensitization to cats was 26% and to dogs 25% 
among the tested population, and a significant increase was observed from 1994 (88). This study 
was based on skin prick test (SPT). In the same study more than 10 % were sensitized to horse, but 
no significant increase over time could be detected. The same trend of increased rate of sensitization 
could be observed in a British study 1996, where 10% of the tested middle-aged men showed IgE 
towards cat, an increase with 6% since 1975 (89). An association between IgE to pets and asthma 
has been reported (90). 
1.5.7 Pet allergens 
The proteins and glycoproteins that humans react towards from pets often belong to the lipocalin 
family but also other protein families have been described (91). Lipocalins, and serum albumins 
have been reported to cross-react (92-94). However, no common feature or effect of these proteins 
explaining why the immune system attack them has been described. The nomenclature of the 
allergens are based on their Latin name and currently named according to the order they were 
reported, so the first cat allergen described is therefore called Fel d 1, after Felis domesticus 1 (95, 
96). Dog allergens are called Can f (after Canis lupus familiaris) and horse allergens are called Equ 
c (Equinius caballus). Seven allergens from cat has been characterized, seven from dog and four 
from horse. 
The most dominant allergen from cat is Fel d 1, a protein belonging to the uteroglobin family and 
found in the saliva and eye. A prevalence of up to 95% among cat sensitized individuals has been 
reported (97-99). For the cat serum albumin, Fel d 2, the prevalence of sensitization is around 20 % 
(93, 99). Fel d 3 belongs to the cystain protein family, and only about 11 % of cat allergic patients 
have been reported to react to this minor allergen (100). Fel d 4 belongs to the lipocalin protein 
family, with a sensitization rate around 60% (101). Cat IgA and IgM are able to bind IgE and were 
designated the allergen names Fel d 5 and Fel d 6 (102). Reported prevalence for Fel d 5 is 40%, 
however no report on the prevalence of sensitization to Fel d 6 is available. The recently identified 
Fel d 7 and Fel d 8, belonging to the lipocalin family and latherin-like family respectively, have 
reported prevalence of 17% and 18%, respectively (103).  
The major dog allergen Can f 1 belongs to the lipocalin family, as do Can f 2, 4 and 6 (94, 104-
106). The prevalence of sensitization is 50%, 25%, 20% and 40%, respectively. The serum albumin 
of dogs, Can f 3, has a reported prevalence of 20 % (93). The kallikrein protein derived from the 
prostatic gland of male dogs has been designated Can f 5, with a reported prevalence of 70% (107). 
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The horse allergen Equ c 1 belongs to the lipocalin family with a reported prevalence of 76% (108, 
109). Also Equ c 2 has been reported as a lipocalin protein, but with lower sensitization prevalence 
and no complete protein sequence reported (110). The serum albumin of horse, Equ c 3, is a minor 
allergen with a prevalence of less than 10 % (111). A surfactant protein belonging to the latherin 
family have been named Equ c 4, with a prevalence of 77 % among horse sensitized individuals 
(112, 113). The previously reported allergen Equ c 5 has been deleted from the IUIS allergen 
database, however the name is still unavailable for registration of new horse allergens. Table 2 for 
presents an overview of allergens from dog, cat and horse (106). 
Table 2 Pet allergens reported allergens from the common pets Dog, Cat and Horse.  
Dog allergen Protein family Size (kDa) 
Reported 
Prevalence 
(%) 
Source 
Can f 1 Lipocalin 23-25 50 Saliva, Dander 
Can f 2 Lipocalin 19 25 Saliva, Dander 
Can f 3 Albumin 69 20 Saliva, Dander 
Can f 4 Lipocalin 16 20 Saliva, Dander 
Can f 5 Kallikrein 28 70 Urine 
Can f 6 Lipocalin 27-29 40 Saliva, Dander 
Can f 7 Epididymal  secretory protein 16 17 - 
Cat allergens       
Fel d 1 Uteroglobin 14-4 95 Saliva 
Fel d 2 Albumin 69 20 Dander, Sera, Urine 
Fel d 3 Cystain 11 10 Dander 
Fel d 4 Lipocalin 22 60 Saliva 
Fel d 5 IgA  400 40 Sera, Saliva 
Fel d 6 IgM 800-1000 Not reported Sera, Saliva 
Fel d 7 Lipocalin 17 38 Saliva 
Fel d 8 Latherin-like protein 24 20 Saliva 
Horse allergens       
Equ c 1 Lipocalin 25 
76 Saliva, Dander, 
Urine 
Equ c 2 Lipocalin 17 50 Dander 
Equ c 3 Albumin 67 >10 Dander, Sera 
Equ c 4 Latherin 17 77 Dander, Saliva 
Equ c 5 (deleted from the database) - - - 
1.5.8 Diagnosis of allergy 
There are several different methods to diagnose allergy that physicians rely on. First, important for 
the physician is the patient’s history. This is supported by in vivo and in vitro diagnostic methods. 
IgE levels are measured in serum against both allergen extracts and against allergens, i.e. the 
specific components (114, 115). Common serum-diagnostic methods include ImmunoCAP and the 
ISAC-chip. Commonly used as well is the SPT, a method when the cellular skin reaction is 
monitored after the application of a small drop of allergen extract, thereafter puncturing of the 
dermis, and the resulting wheal is compared to a negative and positive control (116). To investigate 
the biological relevance of an allergen, an ex vivo test of basophil activation has been developed, 
monitoring the expression of CD63 and CD203c, and when used in clinic referred to as CD-sens 
(117-119). A test positive for allergen specific IgE is not by itself sufficient to diagnose an 
individual with allergy. To do so, an association to allergic symptoms has to be made, ultimately an 
in vivo allergen provocation may be performed. An individual with allergen specific IgE is referred 
to as a sensitized individual. 
In clinical setting, SPT is usually based on the use of naturally occurring allergens in the form of 
allergen extracts. These extract may vary in their content allergen components, and may be hard to 
standardize, making the amount and content of specific components uncertain (120, 121). However, 
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with the introduction of novel technologies in the field of allergology, such as recombinant DNA 
techniques, the possibility to obtain large amount of highly pure allergens has made it possible to 
improve the diagnosis. The diagnosis has expanded from determining the allergen source to the 
exact molecule that the individuals have IgE against (122, 123). 
1.5.9 Treatment of allergy 
The easiest to manage allergy symptoms is probably to avoid exposure of the allergen source. 
Therefore, a correct diagnosis is vital. To complicate matters, some sources such as airborne pollen, 
might be harder to totally avoid. Some allergen sources are ubiquitous and impossible to fully 
avoid, such as mites and fungi, thriving in the same habitat as us humans. To these allergens there 
are symptomatic medicals available, such as antihistamines and corticosteroids, managing 
immediate symptoms and lowering the allergic inflammation. To handle the risk of anaphylactic 
reactions the use of adrenalin is recommended, as a self-injectable alternative (124). The 
development of a humanized anti IgE-antibody, Omalizumab, has created a new treatment regime 
for e.g. severe food allergies. Not only is the circulating IgE abolished, but the also the mast cell 
responsiveness is affected by down regulation of FcRI (125, 126) .  
1.5.10 Allergen-specific immunotherapy 
The only curative treatment for allergic disease today is allergen specific immunotherapy (SIT), 
where repeated exposure of the allergen is executed in a controlled manner. The first report of SIT 
is more than 100 years old, however, the exact mechanism of how the effect of SIT is achieved is 
not fully understood, but apparently the allergen-specific immune response is skewed into non-
inflammatory reaction or tolerance (74, 127). The treatment effect seems to be long lasting (128). 
Several routes of administrations of the allergen (also denoted allergy vaccine) have been developed 
in addition to classic subcutaneous injections, such as sublingual immunotherapy and intra 
lymphatic injections (ILIT)(127). Proposed mechanisms of SIT include the induction of regulatory 
T-cells, and induction of immune suppressive cytokines such as IL-10 and TGF-β (129). IL-10 has 
been reported to affect both allergen specific IgE production as well as dampening the APCs MHC 
II presentation and inflammatory Th2-type of response (130-132). Not contradictory to this 
mechanism, the induction of blocking IgG4 antibodies seems to be another possible mechanism of 
SIT (133-135). One major downside historically has been the concern of safety and reproducibility 
of the extracts normally used as allergy vaccines in SIT (136). Although the quality control of the 
extracts has improved, the development of allergy vaccines produced by recombinant DNA 
techniques have opened the possibility of individualized therapy with specific allergens (137, 138). 
The use of recombinant proteins also opens up the possibility of novel approaches modifying the 
allergens, thereby overcoming safety issues and immunogenic disadvantages of natural proteins 
(139). These strategies are most commonly targeting the IgE –epitopes in order to make the allergy 
vaccines safer. One example of this is the use of peptide vaccines which has been tested in clinical 
trials on cat allergic patients (140, 141). Nevertheless, there is still a risk of systemic activation and 
anaphylaxis, therefore techniques such as ILIT bear much promise, by reducing the number of 
injections and also the amount of allergen injected (142).  
1.6 VACCINATION 
Vaccines are compounds given to individuals to create protection against pathogens (143). 
The vaccines thus aim to create a protective immune response, which for some pathogens is 
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achieved by a humoral response, i.e. a B-cell response and protective antibodies, and for 
others by a cell-mediated response, i.e. a T-cell mediated protection. Vaccines can be given 
orally, injected in different tissues and even applied on punctured skin (143). They usually 
consists of attenuated pathogens or non-pathogenic subunits that can be taken up by DCs and 
presented to the adaptive immunity. The success of vaccines, creating memory to vast part of 
the population at a modest cost is a great achievement of modern medicine, however some 
diseases and pathogens are still without a fully protective vaccine treatment. 
1.6.1 Adjuvants 
Adjuvants are compounds that boost the immune response to a specific antigen, creating a stronger 
response than the antigen alone. Adjuvants are commonly used in vaccination protocols, generating 
a long lasting immunological memory strong enough to prevent a disease or to clear a pathogen 
before it becomes dangerous (144). Historically the most used adjuvants are aluminum compounds, 
such as aluminum hydroxide (Alum) (144). The mechanism of action for of Alum is disputed but 
several ways to achieve the adjuvant effect have been proposed. One suggested theory was the 
activation of innate receptor, therefore a MyD88 and TRIF deficient murine model was used, but 
alum still had an adjuvant effect (145). When alum is injected it forms a depot, and the slow release 
of antigen has also been suggested as an explanation (146). Lately the importance of the depot 
effect has also been questioned, since an immunological effect could be detected within the first 2 
hours after injection (146, 147). The induction of IL-Iβ and the activation of the inflammasome 
NLRP3 has recently been proposed as a key mechanism behind the activation following 
administration of Alum (148). The adjuvant Alum is in particular suited for promoting a humoral 
Th2 response. In many cases a Th1 type response is however required to obtain protection from 
disease. Alum is commonly used in SIT (although not in all countries) despite the fact that it is a 
Th2-promoting adjuvant, which is not favorable in the case of allergy vaccination (149). A lot of 
research is ongoing to find novel adjuvant candidates that may trigger Th1 responses (144). New 
types of adjuvants are now being introduced, such as the emulsion MF59 and the TLR4 ligand MPL 
(144, 150, 151).  
1.6.2 Chitin and chitosan 
Chitin is a naturally occurring carbohydrate polymer consisting of N-acetyl glucosamine, found as a 
building block in cell-walls of fungi and exoskeleton of arthropods. The polymer can be 
deacetylated, by treating chitin with a strong alkali solution. The resulting product is chitosan, 
consisting of N-acetyl glucose amine and glucose amine. Chitosan has been suggested as a potential 
adjuvant, due to its immune-stimulatory properties and its biodegradability (152). Reports from 
studies in mice have revealed that chitosan promoted a mixed Th1/Th2 response (153, 154). 
However, the exact mechanism of how chitosan functions as an immune stimulator is unclear. 
Previous studies using chitosan have concluded that the inflammasome NRLP3 is activated when 
cells take up chitosan in vitro, in contrast to chitin (155, 156). This activation was reported as 
dependent of secondary activations signal —such as TLR signaling, and therefore in line with 
previous findings regarding alum. TLR signaling activates NFκB and upregulate transcription of the 
cytokine pro-IL-1β.The conversion of pro- IL-1β to IL-1β by Caspase-1, a subunit of activated 
NRPL3, is considered the key event of the immune-stimulatory effect. Also the release of IL-18 and 
IL-33 is associated with the activation of the NLRP3 inflammasome. Somewhat contradictory, a 
NLRP3 and caspase-1 deficient murine models show similar levels of antibodies as wild type mice 
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after treatment with diesel particles (157). The role of NLPL3 in the immune activation of chitosan 
is debated and needs further studies. Recently published work shows that chitosan has the ability to 
promote the cytosolic DNA sensor cGAS-STING pathways, and promote DC maturation and type 1 
IFN (158).  
1.6.3 ViscoGel 
ViscoGel is a chitosan-based viscoelastic hydrogel made up by 1% chitosan and 99% water 
(159). ViscoGel has a randomized pattern of deacetylation, making the chitosan more soluble 
than conventional chitosan with blockwise deacetylation. Thus, the chitosan used in Viscogel 
is soluble at physiological pH, making ViscoGel suitable for use in medical applications. The 
gel can be processed into particles of defined size. Promising results have been reporter from 
a mouse study were ViscoGel was injected in combination with Haemophilus influenzae type 
b (Act-HIB) vaccine (153). Administration of ViscoGel enhanced the antibody response to 
Act-HIB. When analyzing the cellular response, the cytokines upregulated indicated both a 
Th1 and Th2 response, making ViscoGel an interesting adjuvant candidate to study further. 
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2 AIM OF THE THESIS 
The overall aim of this thesis was to develop new approaches to correctly diagnose 
individuals allergic to dog and horse, and identify the molecules causing sensitization to these 
animals. This knowledge could be used development of immune modulating therapies. 
However, today’s approved immune stimulating compounds applied in vaccination could be 
improved, therefore this thesis also investigated a novel adjuvant candidate, the chitosan-
based hydrogel Viscogel. 
The specific objectives of the thesis were: 
I To investigate the allergenicity of dog saliva, and compare it with a commercially available 
extract based on dog dander.  
II To identify new allergens from horse and to evaluate IgE reactivity among horse sensitized 
individuals to the previously unknown, as well as to known horse allergens. 
III To investigate how the chitosan based adjuvant candidate ViscoGel is taken up by antigen 
presenting cells and mechanisms of cell activation. 
IV To evaluate safety and immune stimulating effect of ViscoGel in a clinical phase I/IIa 
trial, where ViscoGel was evaluated as an adjuvant for the model vaccine Act-HIB. 
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3 MATERIAL AND METHODS 
Methods and techniques used in this thesis are briefly described here. For a more 
comprehensive description please refer to material and methods in each paper. 
3.1 SUBJECTS 
In paper I sera from dog allergic, or dog sensitized individuals were collected. Sera obtained 
from these individuals were used to measure IgE against dog dander extract, and dog saliva. 
Blood samples were taken from patients with dog allergy diagnosis, to perform basophil 
activation test. 
For paper II, sera from subjects with positive IgE to horse dander extract (HDE), according 
to ImmunoCAP test, were collected.  
In paper IV, in total 120 healthy volunteers of both sexes, age 22-50 years, participated in 
the two separate parts of the clinical trial.  
All studies were approved by the local ethics committee. 
3.2 MICE 
In paper III, C57BL/6 mice were used for in vivo evaluation of the local effect after 
subcutaneous injection of the viscoelastic hydrogel ViscoGel.  
This study was approved by the local committee for animal welfare.  
3.3 METHODS  
3.3.1 Enzyme linked immunosorbent assay (ELISA) (paper I, II, and III) 
Two different ELISAs were developed for detecting IgE using monoclonal antibodies to 
human IgE. In paper I, dog dander extract ELISA was validated against IgE values obtained 
from ImmunoCAP. In paper II, an IgE standard was developed using a humanized 
monoclonal IgE with known kUA/l value, and used as a reference. IL-1β and IL-18 were 
measured using commercial ELISA kits in paper III. 
3.3.2 Flow cytometry (paper I and III)  
Cell surface- and intracellular markers were detected with fluorophore conjugated antibodies 
using multicolor flow cytometry. The chitosan based hydrogel ViscoGel was labelled with 
FITC and cell uptake analyzed by flow cytometry. Results were analyzed using the FlowJo 
program. 
3.3.3 Confocal laser scanning microscopy (paper III) 
Confocal laser scanning microscopy was used to visualize internalized labeled ViscoGel.  
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3.3.4 Basophil activation test (BAT) (paper I)  
To evaluate the degree of degranulation of basophils, whole blood samples from allergic 
donors were treated with the allergen of interest, followed by analysis of the basophil marker 
CD203c and surface expression of the granulae marker CD63 by flow cytometry. 
3.3.5 THP-1 cells and monocyte derived DCs (MDDC) (paper III) 
THP-1 cells with reporter gene for NFκB were differentiated into THP-1 derived 
macrophages by 72 hours incubation with phorbol 12-myristate 13-acetat (PMA) and 
MDDCs were differentiated from peripheral blood mononuclear cells (PBMC) using IL-4 
and GM-CSF were cultivated and used for investigating uptake of Viscogel, and stimulation 
of innate responses. 
3.3.6 Cellular responses (paper IV) 
A cell proliferation assay was applied on PBMC samples to measure the incorporation of 
[3H]-thymidine, after stimulation with antigens. ELISpot was used to assess the amount of 
IFN producing cells after stimulation with antigen, and a multiplex assay was used to 
measure cytokines from the cell supernatant after stimulation. 
3.3.7 Production of recombinant proteins (paper II) 
DNA encoding full-length allergens and adjusted for expression of rare Escheria coli codons, 
were cloned into expression vectors and his-tagged recombinant protein were produced in E. 
coli using a BL21 expression system. 
3.3.8 Protein purification (Paper II) 
Recombinant His-tagged proteins were purified by immobilized metal chelating 
chromatography (IMAC) and size exclusion chromatography (SEC). Proteins from natural 
source were purified with SEC and ion exchange chromatography. 
3.3.9 Protein separation (paper I and II) 
Electrophoric separation of proteins was conducted using sodium dodecyl sulfate - 
polyacrylamide gel electrophoresis (SDS-PAGE), a method were proteins are separated 
according to size, and in paper I 2D electrophoresis was used to separate protein according 
to size and iso-electric point. 
3.3.10 Immunoblotting (paper I and II) 
To detect IgE binding proteins, allergen extracts were separated using SDS-PAGE or 2D 
electrophoresis, and thereafter transferred to a nitrocellulose membrane and proteins were 
detected using sera and IgE detection antibodies. 
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3.3.11 Proteomics (Paper I and II) 
Isolated protein bands were subjected to in-gel tryptic digestion and mass spectrometry and 
database search Blast search was used to identify potential allergens, following Tandem mass 
spectrometry (MS/MS) analysis, or by using reported peptide sequences. 
3.3.12 ImmunoCAP (paper I and II) 
ImmunoCAP analyses were performed to measure IgE against the dog dander extract and 
HDE, and for the selection of IgE negative serum. 
3.3.13 Statistical methods (paper I-IV) 
In paper I, Spearman rank test was used for correlation analysis. In paper II linear 
regression was analyzed for antibody responses. In paper III levels of uptake, NFκB, IL-1β 
and IL-18 were analyzed using the parametric one-way ANOVA and Tukey´s multiple 
comparison test, after testing for normal distribution. In paper IV, descriptive statistics were 
used for demographic and safety data, and antibody responses were assessed using analysis of 
covariance and cellular response were analyzed with Kruskal–Wallis with Dunn's multiple 
comparisons test and Wilcoxon matched pairs test. P < .05 was considered significant. 
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4 RESULTS AND DISCUSSION 
4.1 EVALUATION OF DOG SALIVA AS AN ALLERGEN SOURCE 
In paper I we investigated dog saliva as an allergen source. Allergy to dog is a common 
allergy worldwide, affecting between 5-10% of the population (160-162). Seven molecules 
have been identified as allergens from dog (95, 96). Today’s diagnostics and SIT are based on 
allergen extracts, however the content of allergens in dog dander extract is questioned (120, 
163). To our knowledge, no study has previously been done to determine if allergens are 
present in dog saliva, and to what degree. Therefore we collected saliva from individual dogs, 
all under sterile conditions to avoid contamination, and a saliva extract was produced.  
The dog saliva extract was tested using a validated ELISA, and compared with commercially 
available dog dander extract using sera from dog sensitized individuals (n=59) (Figure 6). Of 
the tested sera, 44 showed a positive IgE binding to saliva (Optical density (OD); median, 
0.276; range, 0.123–0.891). A portion of the tested sera (23/53; 39%) had a higher IgE 
reactivity to saliva than to dander, implying that saliva extract contained a different 
composition of allergens than the dog dander extract, when tested in the validated ELISA. To 
investigate if the saliva extract could help identifying IgE positivity among subjects with 
suspected dog allergic symptoms, 55 sera with reported symptoms but with negative IgE 
value to dog dander extract as measured on ImmunoCAP e5 was tested. In this group 11 had 
a positive IgE result to the saliva extract (OD; median, 0.139; range, 0.125–0.188). This 
result further implies the possible role of saliva in sensitization among dog allergic subjects. 
 
Figure 6 IgE reactivity of dog saliva. A Correlation between IgE reactivity to dog dander by ELISA and ImmunoCAP 
results using dog dander extract, where the Y-axis denotes OD value for saliva extract and the x-axis denotes e5 ImmunCAP 
value (n = 20); (B) correlation between IgE reactivity in ELISA to dog dander extract and dog saliva extract, where the y-axis 
denotes the dog dander extract O.D. value and the x-axis denotes the saliva extracts OD value., r2 – correlation factor. (n = 
59);  
Allergenic activity of the saliva extract was then investigated using the biologically relevant 
BAT for testing. Three subjects were enrolled to this part of the study (ImmunoCAP e5: 0.1, 
2.2 and 2.6 kUA/l). Blood samples were collected and red blood cells were lysed and 
removed, and the remaining cells were stimulated with dilution series of dog dander extracts 
and dog saliva extract. All three subjects, with doctors’ diagnosis of allergy to dog, showed 
an up regulation of both tested parameters, CD203c and CD63, however the basophils of one 
of the tested patients were not reacting to the dog dander extract (Figure 7). This result is in-
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line with the previous ELISA finding that some individuals seems to have higher IgE titers, 
or IgE exclusively to dog saliva.  
We also investigated SDS-PAGE of both the extracts, and IgE immunoblotting was 
performed using a pool of sera from dog sensitized individuals. The protein bands from the 
SDS-PAGE corresponding to IgE binding bands on immunoblot were cut out and analyzed 
using the MS/MS and MASCOT software. Can f 1 to 4 and Can f 6 could be detected in the 
dog dander extract, but no Can f 4 could be identified from the IgE binding bands from 
saliva. Additionally, four candidate IgE binding proteins were identified. These identified 
proteins need to be verified, since the possibility of co-migration with other proteins in the gel 
cannot be excluded. 
 Individual saliva samples, as well as dander, from different dog breeds were also analyzed 
against pooled sera (figure 8). We could conclude that a high number of IgE binding bands 
detected between 14 kDa and 67 kDa from all the dogs. A great individual variation in the 
patterns of IgE binding could be observed, however a tendency of fewer IgE binding bands 
could be observed for the tested golden retriever. The sample size in this study is to low, but 
may indicate that the allergen levels of this dog breed is lower, which has been described 
before in the literature (164).  
In conclusion this study showed that dog saliva may improve the IgE based diagnostics if 
added as an allergen source when evaluating IgE levels against dog. Moreover, the 
biologically relevant test, BAT, confirmed that some patients may only react to dog saliva 
extract. 
 
Figure 7 Basophil activation testing of three dog allergic individuals Y-axis denotes %-up regulated basophil markers CD 
63 and CD203c after activation by dog dander extract or dog saliva extract, and the x-axis concentration in 10 fold serial 
dilutions, from right to left 10 μg/mL to 10-7 μg/ml. 
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Figure 8 SDS-PAGE and immunoblot analysis of saliva from different dog breeds visualized with a pool of dog-allergic 
patients sera. Lanes indicate m, Molecular weight markers; 1. German Wirehaired Pointer, male; 2. German Shorthaired 
Pointer, male; 3. German Shepherd Dog, male; 4. Cocker Spaniel, male; 5. Cocker Spaniel, bitch; 6. Doberman Pinscher, 
male; 7. Doberman Pinscher, bitch; 8. Neapolitan Mastiff, male; 9. Dogue de Bordeaux, male; 10. Saint Bernard's Dog, bitch; 
11. Golden Retriever, male; 12. Pekingese, bitch; 13. Mixed breed, bitch; 14. Mixed breed, bitch. Pooled sera from 13 
individuals was used. 
4.2 IGE PROFILE IN HORSE (EQUUS CABALLUS) SENSITIZED SUBJECTS USING 
NOVEL AND PREVIUSLY DESCRIBED ALLERGENS 
In paper II we applied methods similar to the ones in Paper I, but to another allergen source, 
the horse. First we collected 100 consecutive sera with IgE levels >0.35 kUA/l against the 
commercial HDE, ImmunoCAP e3 (HDE-e3). Additionally 50 consecutive sera were 
collected, as negative controls, with IgE <0.35kUA/l when tested on ImmunCAP Phadiatope 
(IgE measurement of 11 allergen sources including HDE), as well as to the main pet allergens 
rCan f 1, rFeld 1 and rEqu c 1. 
An initial immunoblot revealed an IgE binding band of 14 kDa. The corresponding SDS-
PAGE band was cut out and subjected to MS/MS protein analysis. The analysis revealed a 
protein not previously described as a horse allergen, however this protein showed similarity 
to a previously described allergen from cow (165). This protein was cloned and expressed as 
a fusion protein in E. coli, purified using IMAC and SEC and denoted as Equ c 7. 
Furthermore, two protein bands of 5 and 10 kDa from SDS-PAGE separation of HDE 
revealed homology with the previous described major cat allergen Fel d 1 (99) using MS/MS 
analysis followed by data base search. This protein was designated Equ c 6. Full-length Equ c 
2, previously identified as two protein fragments (166), was identified using BLASTP data 
base search. Recombinant Equ c 2 was expressed and purified. In addition to these three 
previously not characterized horse allergen candidates, Equ c 1, previously known as a major 
allergen, was expressed as a recombinant protein and purified, and Equ c 3 and 4 were 
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purified from HDE and horse serum, respectively. To determine IgE levels in-house ELISA:s 
with IgE standard was developed.  
 
IgE levels were measured in the 100 consecutive HDE positive subject’s sera as well as in 
sera from the 50 negative subjects. IgE values > 0.35 kUA/l were considered positive. The 
rate of sensitization to the novel allergens was 66, 36 and 34 % for rEqu c 2, rEqu c 6 and 
rEqu c 7 (median 3.38, 9,59 and 1.71 kUA/l), respectively. Interestingly, several of the 
negative control sera showed IgE binding to rEqu c 7 (figure 9). When analyzing correlation 
with the HDE-e3 value only a weak correlation was observed. This might reflect that this 
allergen is present at an inadequate level in HDE-e3, or possibly be due to cross-reaction to 
Bos d 3, the cow homologue to Equ c 7, since the selection criteria did not exclude sera from 
cow sensitized individuals. 
rEqu c 2 was produced as a full-length recombinant protein, to our knolledge, for the first 
time. A considreble portion of the tested positive subjects’ sera showed IgE levels against this 
allergen, and a higher proportion were positive to rEqu c 2 (66 %), than to the major horse 
allergen rEqu c1 (61 %). Belonging to the lipocalin family, this protein will be intersting to 
study furter, considering the high degree of cross-reactivity observed among allergens  in this 
protein family (94). For rEqu c 6 34 % of the tested sera showed a positive result, and as in 
the case for Equ c 2, the posibility to evauate potential cross-reactivity would be of great 
interest, considering the homology to the major cat allergen Fel d 1 .This is the first time this 
allergen has been reported in the scientific litrature. nEqu c 4 showed a similar trend among 
the sera used as negative controll as rEqu c 7, with several clearly positive subjects. Therfore 
one might draw the same conclusions as for rEqu c 7, i.e. low levels present in HDE-e3 may 
generate false negative results and thus negatively influencing the selection  criteria for the 
control group.  
The previously described allergens evaluated in this study, rEqu c 1, nEqu c 3 and nEqu c 4, 
together with the two novel allergen candidates Equ c 6 and 7, and the full length Equ c 2, 
showed the same rate of positive IgE results as the HDE-e3, with 100% of the subjects tested 
positive to at least one of the allergens (figure 10). To our knowledge, this is the first time 
components could meet the standards of extract based diagnosics. In conclusion, in paper II 
we evaluated 3 novel full-length horse proteins for their ability to bind IgE in sera from horse 
sensitized sunbjects. The novel horse allergen candidates identified, add to the list of 
components that might cause allergic disease and will possibly contribute to improved future 
diagnostics and SIT. 
  33 
rE q u  c  7
k
U
A
/l
 I
g
E
p
o
s
. 
s
u
b
j.
 n
e
g
. 
c
o
n
tr
.
0
1
2
3
4
5
2 0
4 0
6 0
8 0
1 0 0
rE q u  c  6
k
U
A
/l
 I
g
E
p
o
s
. 
s
u
b
j.
n
e
g
. 
c
o
n
tr
.
0
1
2
3
4
5
5 0
1 0 0
1 5 0
2 0 0
2 5 0
rE q u  c  2
k
U
A
/l
 I
g
E
p
o
s
. 
s
u
b
j.
n
e
g
. 
c
o
n
tr
.
0
1
2
3
4
5
1 0
2 0
3 0
4 0
CBA
 
Figure 9 IgE levels to rEqu c 2, rEqu c 6 and rEqu c 7. Levels of IgE in sera from 100 HDE-e3 positive subjects and 50 
negative control subjects, as measured by quantitative IgE ELISA, against the horse allergens. The Y-axes indicate IgE levels 
in kUA/l and the dotted line indicates 0.35 kUA/l. Mean value and one standard deviation are indicated.
 
Figure 10 IgE levels to HDE-e3 and the allergen components rEqu c 1-7. Serum levels of IgE against the allergen 
components and HDE-e3 among horse sensitized individuals, X-bar indicates IgE levels in kUA/l , and bar indicate mean 
value and one standard deviation, n=100.  
   
4.3  UPTAKE OF CHITOSAN-BASED VISCOELASTIC HYDROGEL PARTICLES 
BY ANTIGEN PRESENTING CELLS AND ACTIVATION OF INNATE IMMUNE 
RESPONSES 
In paper III we aimed to evaluate the potential adjuvant ViscoGel, a chitosan-based 
viscoelastic particulate hydrogel, for its ability to be taken up by APCs and to activate the 
innate immune system. Chitosan has been proposed as an immune modulator with several 
properties that are favorable to adjuvant use, such as  being biodegradable, non-toxic and to 
stimulate adaptive immunity, both Th1 and Th2 type responses (153). In terms of allergen 
vaccination by SIT, such a mixed immune response could be favorable (74). Moreover, the 
possibility of covalent linking of proteins to the viscoelastic chitosan particles provides a 
means to prevent systemic spread of the vaccine after injection, addressing safety issues 
concerning risk for systemic reactions in SIT. Thus chitosan, and ViscoGel in particular, 
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could be an interesting adjuvant candidate for application in allergy vaccination, as well as in 
many prophylactic vaccines that have to induce both humoral and cellular immunity to create 
protection. In order to further investigate the feasibility to apply ViscoGel as an adjuvant and 
vaccine vehicle, mechanisms of immune activation for the chitosan-based viscoelastic gel 
particles need to be elucidated. In this study the ability of APC:s to take up and process the 
viscoelastic chitosan particles was investigated, and furthermore how activation of immune 
cells is achieved.  
We derived macrophage-like cells from the THP-1 cell line, by treating the cells with a 
stimulator, PMA. Thereafter the THP-1 derived macrophages were stimulated with FITC-
labeled viscoelastic particles of two sizes, 10 µm and 200 µm, and the percentage of FITC 
positive cells was measured using flow cytometry (167). To inhibit uptake cells were treated 
with the cytochalasin D, a broad inhibitor of uptake acting on actin filaments. Extracellular 
and intracellular staining was distinguished by quenching the intracellular signal. Particles of 
both sizes were taken up, and a significant inhibition could be detected following treatment 
with cytochalasin D, however only a significant reduction of signal could be achieved for 
particles of 10 µm size. To verify the uptake, cells were visualized using laser scanning 
microscopy, and z-stack scanning verified internalization of the hydrogel (figure 11). 
Internalized particles appeared to be around 2-5 µm in size and FITC positive cells could be 
detected for cells incubated either with 10 µm or 200 µm particles after 24 hours. To further 
investigate the uptake we differentiated MDDC:s from human PBMCs, and measured the 
uptake using flow cytometry. These cells were able to readily take up particles in an actin 
dependent manner. 
To investigate the immunological response, the NFκB reporter gene system of the THP-1-
blue cell line was used, making monitoring of immune activation possible. The hydrogel was 
able to activate NFκB to a significant degree when compared to unstimulated cells or cells 
stimulated with the adjuvant alum. To further analyze if the response could be enhance by 
engagement of the TLR-4 signaling pathway, cells were pretreated with LPS before 
incubation with the viscoelastic chitosan particles or alum. No additive effect could be 
detected in the LPS pretreated cells, either for the viscoelastic chitosan particles or for alum. 
NFκB triggers transcription of pro-IL-1β, which is processed to active IL-1β via an 
inflammasome pathway. Therefore IL-1β was measured in cell culture supernatants by 
ELISA (148). The hydrogel particles induced a significant enhanced IL-1β response in the 
THP-1 derived macrophages, compared with alum stimulated and untreated control cells 
(figure 12). Alum was only able to stimulate IL-1β production in combination with a TLR 
ligand, in this case LPS, and to a significant higher degree than the hydrogel particles, in line 
with previous reports (148).  The hydrogel stimulated did not significantly enhance IL-1β 
secretion cells in combination with LPS. To support this finding in vivo, exudates from mice 
subcutaneously injected with the viscoelastic hydrogel (200 µm particles) were analyzed after 
4 hours and 24 hours post injection, and an up-regulation of IL-1β was detected compared to 
exudates from exudates from PBS- injected sites. Previous reports on chitosan particles have 
concluded that the activation pathway is dependent on caspase-1 activity, therefore we 
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investigated this proposed mechanism using FLICA, a fluorescent compound that binds to 
caspase-1, and we analyzed the cells using flow cytometry (155, 156).  No up-regulation of 
caspase-1 could be detected for the chitosan hydrogel stimulated cells, either alone or in 
combination with LPS, thought alum elicited an up-regulation as previously reported.   
To conclude, in this study we show that chitosan based viscoelastic particles are taken up by 
APCs, and that the internalization is actin dependent. In contrast to other reports, we also 
detected an activation of NFκB and upregulation of IL-1β, and the IL-1β independent of TLR 
signaling (156). 
 
Figure 11 Uptake of ViscoGel by THP-1 derived macrophages. A-D Analysis by confocal laser scanning 
microscopy of THP-1 derived macrophages incubated with 10 µm FITC labeled viscoelastic chitosan particels 
(green) for 2 hours (A), 6 hours (B) or 24 hours (C) and 200 µm particles for 24 hours (D). Cell membranes 
were stained using Cell Mask orange (red). 40x magnification, scale bar indicates size A 20 µm and B-C 10 µm 
 
Figure 12 ViscoGel stimulate the production of IL-1β. IL-1β measured in supernatants of THP-1 derived 
macrophages after 24 hours stimulation with ViscoGel of 10 and 200 µm size, and with alum, alone (-LPS) or 
with the addition of LPS (+LPS). Data presented as mean plus SD. Statistical analysis was performed using one 
way ANOVA Tukey´s multiple compairsion. The concentration of IL-1 β in cultures of unstimulated cells was 
set to 62.5 pg/ml, i.e. the detection limit of the assay, since all data points were ≤62.5 pg/ml.   *= p<0.05, 
**=p<0.01***=p<0.005 . VEP=ViscoGel particles, unst=cells incubated in medium alone 
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4.4 EVALUATION OF SAFETY AND EFFICACY OF VISCOGEL IN A SINGLE-
BLIND RANDOMISED PHASE I/IIA CLINICAL TRIAL 
To study safety and the adjuvant effect of the chitosan particles, i.e. ViscoGel, a randomized 
phase I/IIa clinical trial was conducted, paper IV. Healthy volunteers included in the study 
were between 22-50 year of age and of both sexes. Subjects included had no reported 
Haemophilus influenza type B (HIB) infection, or contact with individuals with HIB, and had 
not received previous vaccination against HIB with the vaccine Act-HIB.   
In the first part of the study, the primary objective was to investigate the safety of 
intramuscular injected ViscoGel. This first part also served as dose-finding for the second, 
phase IIa, part of the study. Three groups with ten healthy volunteers per group received 
intramuscular injections with Viscogel (gel particle size 200 µm) in escalating doses, 25, 50 
or 75 mg (one dose per group). Safety was monitored and adverse events (AE) were 
registered. A drug safety monitoring board evaluated the result prior to any dose escalation 
and after completion. The Viscogel was well tolerated at all doses, and no serious adverse 
events were reported. The highest number of AE:s were observed for the 75 mg group. A 
majority of reported AE:s was mild to moderate. The dose for the second phase was selected 
to 50 mg, based on lower incidence of local reaction at the injection site. 
In the second part of the trial, efficacy of ViscoGel as an adjuvant was evaluated, as well as 
the safety. To evaluate the efficacy, ViscoGel was used as an adjuvant for Act-HIB, which 
was used as a model vaccine. In this part of the study, the participants were randomized to 
one of five groups with 20 healthy volunteers in each. The subjects were given one 
intramuscular injection with 0.2 µg Act-HIB with or without ViscoGel, 2 µg Act-HIB with 
our without ViscoGel, or the standard dose 10 µg of Act-HIB alone. Serum samples were 
collected at day 0 (prior to injection) and at day 4, 7, 14, 28 and 180 post injection. Act-HIB 
IgG titers were evaluated using an anti-HIB ELISA validated for clinical use.  To evaluate 
cellular response, whole blood was collected at day 0 and 7 and PBMC were isolated and 
frozen. After thawing of the cells, cell cultures were stimulated with Act-HIB, tetanus toxoid 
(TT; as a control for TT present in Act-HIB), or influenza antigen (irrelevant antigen control). 
The cellular response was assessed by IFNγ ELISpot, cell proliferation and secreted cytokine 
analyses.  
No severe AEs were reported in the second part of the study. A higher incidence of AEs was 
reported in the groups injected with the combination of Act-HIB and ViscoGel, compared to 
Act-HIB alone. The primary efficacy was measured as change in IgG levels against Act-HIB 
at day 28. The highest antibody titers were reported for the 10 µg Act-HIB group, and no 
significant difference could be detected between the subjects that were injected with a 
combination of ViscoGel/Act-HIB and those receiving the corresponding Act-HIB dose. To 
further analyze the IgG result, due to high base-line titers measured at day 0, a subgroup 
analysis was performed. Subjects were divided according to lower base-line titers, and the 
anti-Act-HIB titers at day 28 were measured for subjects within the three lower quartiles and 
the lower half of baseline titers, however no difference between the groups injected with 
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ViscoGel/Act-HIB could be detected compared to those given the corresponding Act-HIB 
dose. The cellular response after stimulation with Act-HIB, measured by IFN ELISpot, 
showed a significant up regulation of IFN positive cells in the ViscoGel/ 2 µg Act-HIB 
group at day 7 compared to baseline (day 0), while a significant decrease in the IFN 
response could be detected for two of the groups receiving only Act-HIB, the 0.2 µg and 2µg 
group (figure 13). To further analyze the cellular response in the groups, PBMCs were 
stimulated with influenza antigen, and all groups receiving Act-HIB without ViscoGel 
showed a significant reduction in IFN- producing cells at day 7. Interestingly, ViscoGel 
seemed to counteract this reduction. Secreted cytokines were analyzed supernatants of 
PBMC-cultures from the 2 μg ViscoGel/Act-HIB and 2 μg Act-HIB groups. A significant 
increase in IFN could be detected at day 7 for the ViscoGel/Act-HIB group. This was 
observed after in vitro stimulation with both Act-HIB and influenza antigen stimulation.  
IL-2, IL-4, IL-5, IL-10, IL-17A and TNFα was also analyzed but no change could be detected 
between day 0 and 7 for these cytokines. 
 
Figure 13 IFN-γ response analyzed by ELISpot in PBMC cultures in vitro stimulated with Act-HIB (A) and influenza 
antigen (B). The number of stimulated IFN-γ producing cells per 100,000 PBMCs at Day 0 (open bars) and Day 7 (black 
bars) are shown as mean ± SEM of net values where the background IFN-γ producing cell number is subtracted. *p < 0.05, 
**p < 0.01, ***p < 0.001; Wilcoxon signed rank test. VG denotes ViscoGel 
 
 
To evaluate proliferation, incorporation of 3H thymidine was analyzed. No change in Act-
HIB or influenza antigen stimulated proliferation between day 0 and 7 samples was be 
observed. 
This first-in-man study with the chitosan based hydrogel ViscoGel, showed that ViscoGel is 
well tolerated in the 70 healthy volunteers subjected to intramuscular injection of ViscoGel. 
In contrast to previous reports from mice, no effect on the antibody production following 
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administration of ViscoGel could be observed (153). Compared to a previous Swedish study 
on anti-HIB titers in the general population, the base-line IgG titers that we found in this trial 
among subject unvaccinated to Act-HIB were higher than expected (168). This complicated 
the evaluation of the antibody response in our study. However also the selection of the Act-
HIB as a model vaccine might have masked a possible adjuvant effect of ViscoGel, The Act-
HIB vaccine is composed of the bacterial polysaccharide conjugated to TT with a good 
immune stimulatory capacity and a previous study has showed that alum do not increase the 
anti-HIB responses to such conjugated vaccines (169). The most striking effect of ViscoGel 
administration was that the chitosan gel seemed to counteract the reduction of the IFN- 
response seen for subjects given the Act-HIB vaccine alone (figure 13). In contrast, subjects 
that received Act-HIB in combination with ViscoGel displayed a slight up regulation of the 
IFN- response (figure 13). 
4.5 ETHICAL CONSIDERATIONS 
All of these studies have been conducted in accordance with ethical approval from the 
Swedish authorities. Paper IV describes a first-in-man trial, where all cautions has to be 
taken that patients may react unexpectedly. Paper I-III were all studies performed on human 
material were conducted in vitro, therefore the risk of harming any subjects could be 
neglected after the blood was collected. All the subject in paper IV were healthy volunteers. 
Personal data were treated anonymous and no results could be tracked to individuals when 
reported. This is vital for protecting integrity. Following guidelines is of high importance in 
any research conducted. In particular, long term effects of participating subjects in clinical 
trials must be carefully considered and the high safety demands have to be met. Also how 
research is reported in the scientific literature and to the public is vital. The recruitment of 
volunteers as participants in research are important, and one might argue that research 
conducted without the patient’s best in focus may reduce the voluntary participation in the 
long run. 
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5 FUTURE PERSPECTIVES  
This thesis focuses on several important aspects on improvement of the management of 
allergy towards pets, in terms of treatment and diagnostics. It is also valid for the field of 
adjuvant research in general, examining a novel chitosan based adjuvant candidate. In paper 
I we examined dog saliva as an allergen source, and could show that the saliva extract could 
identify subjects with possible dog allergy, even though they were negative when analyzing 
IgE values against dog dander extract. Therefore one might argue that either there are 
allergens missing from the dander extract that are present in saliva, or the amount of each 
component is not sufficient enough to be used for detecting allergen specific IgE. One way to 
overcome such problems could be to spike the dander extract with saliva extract, making a 
mix of both extracts (170). To address problems with limited amount of several components 
in the extract, one might argue that there is a need to standardize and quantify allergens 
present in the extracts and spike the extract with missing components (171).  
In paper I we also identified four IgE binding proteins not corresponding to known dog 
allergens. It would be of high interest to evaluate these proteins further, to confirm that they 
are IgE binding. The identified proteins were BPIFA2, Mucin-5B, ANGPTL5 and the IgA 
heavy chain constant region. The only of these candidates that has homology with other 
reported allergens is IgA (102, 172). However, in the case of IgA, which has been described 
as a pet allergen in cat (Fel d 5), the IgE binding epitope is the carbohydrate galactose-α-1,3-
galactose (α-Gal), not the protein per se. The other identified proteins show no striking 
feature that is common to any known allergen or allergen protein family. If confirmed as IgE 
binding proteins, they are new dog and pet allergens that should be studied further. 
In paper II we identified three novel IgE binding proteins from horse. The first one, denoted 
Equ c 2, was previously only identified as smaller fragment. To further investigate this 
protein as an allergen, analysis by BAT would be highly interesting to perform. This would 
allow for testing of the allergenicity in a biologically relevant setting, which is desirable 
especially as the prevalence of IgE-binding to full length Equ c 2 was higher than the 
prevalence previously reported for Equ c 1. As Equ c 2 is a member of the lipocalin family, it 
would be of high interest to examine cross-reactivity with other species, such as dog and cat 
(92). This is also interesting for the other two allergens identified, denoted Equ c 6 and 7, 
showing homology with the major cat allergen Fel d 1 and the minor cow allergen Bos d 3, 
respectively(173, 174). Future aims would also include testing these allergens’ ability to 
activate basophils in BAT. One might also speculate that a possible route of sensitization to 
Equ c 6 could rather be via cow-horse allergy, with cow acting as the primary source of 
allergens. This might explain the high prevalence of sensitization among subjects without 
reported contact to horse (175). The reasons why certain proteins are more prone to cause 
sensitization and allergic reactions are still debated. Some data have demonstrated that 
allergens can cause innate immune activation via TLRs (70). Both the Equ c 2 and Equ c 6 
are potential activators of TLR4, however human psoriasin (homologue to Equ c 7) can 
function as a ligand to the PRR RAGE (176). Thus all the novel IgE binding allergens 
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presented in paper II have reported homologues with ability to signal via PRRs, a subject 
that would be exciting to explore further. 
Paper I and II both give new insights to the complex pattern of allergen components that 
individuals might be allergic to. Any expansion of knowledge concerning new allergen 
components might be beneficial in terms of diagnostics, but also, in the long run, for SIT 
(177). Several studies using dog dander for SIT have showed that the extracts are not as 
efficient as for cat (178, 179). Therefore, studies identifying new allergen candidates, as 
shown in this thesis,  may contribute to the development of future personalized diagnostics 
and treatment by facilitating correct selection of patients according to their reaction profile 
against specific allergen components.  
To evaluate the potential adjuvant properties of ViscoGel, we investigated the chitosan based 
particles for their ability to be taken up by, and activate APCs (paper III). Both sizes, 10 and 
200 µm were taken up, and this effect was possible to block using a broad inhibitor of actin 
dependent phagocytosis. Therefore, to investigate the exact route by which ViscoGel is taken 
up would be of interest, and if route influences the immunological effect (180). A surprising 
result was the ViscoGel stimulated up-regulation of IL-1β, without any caspase-1 
involvement (181, 182). To speculate, the activation of APCs in vivo might be different from 
in vitro. It would be highly interesting to investigate the effect of ViscoGel in IL-1β deficient 
mice, to elucidate the importance of this activation mechanism. Also of interest is the 
opportunity to elucidate the importance of variable characteristics of the chitosan included in 
ViscoGel, e.g. the degree of deacetylation or the net charge of the molecule (156). ViscoGel 
has a randomized deacetylation pattern, in contrast to other chitosan formulations, with 
blocks wise deacetylation. To investigate if the net charge of the adjuvant can influence the 
immune activation, ViscoGel could be a suitable compound for such experiments.  
Paper IV gave us the opportunity to study the effect of ViscoGel in humans, for its safety 
and as a candidate adjuvant. In summary, no significant safety concerns were reported, 
supporting the application in humans. However, the immune stimulating effect of ViscoGel 
was not as good as expected, showing no significant enhancement of the antibody response. 
One might argue that this study detected an up regulation in a Th1 type response, but more 
striking was the finding that ViscoGel seemed to counteract the reduced IFN responses 
observed when the vaccine Act-HIB was given alone. This makes ViscoGel highly 
interesting in SIT, to promote a more Th1 type response, or at least brake the dominance of 
the Th2 response. Not previously addressed in this paper, the ViscoGel manufacturing 
process allows cross-linking of the chitosan with proteins. This is an advantageous property 
for application in SIT, by allowing SIT without the risk of systemic spreading of the allergen. 
ViscoGel could thus be a suitable candidate for improving SIT, and would be interesting to 
study further in such settings (183). 
To conclude, paper I and II identifies novel allergen sources and components, with potential 
to improve diagnostics, and immunotherapy, and paper III and IV addresses the adjuvant 
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properties of the chitosan viscoelastic gel ViscoGel, showing several promising 
characteristics for improvement of current SIT protocols.  
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Allergi är en vanlig sjukdom som upp emot 30 % av befolkningen lider av. Denna sjukdom 
yttrar sig som en överkänslighetsreaktion mot ett främmande och oftast ofarligt protein. 
Reaktionen ger upphov till symptom som rinnande näsa och ögon, svullnad och klåda, eksem 
och pipig andning. Dock kan även allergiska reaktioner leda till allvarligare komplikationer 
så som astma, och anafylaktisk chock, som är livshotande. Ämnet man reagerar på kallas 
allergen, och är oftast ett protein. Vanliga allergenkällor att reagera på är pollen, födoämnen 
som fisk och nötter, kvalster och pälsdjur. Den typ av allergi som behandlas i denna 
avhandling avser IgE-medierad allergi, som är den vanligaste typen. IgE är en antikropp och 
de proteiner som IgE binder till definieras som allergen. Denna antikropp kan när den bundit 
allergen aktivera celler i vävnad eller blod, s.k. mastceller och basofiler. När dessa celler 
aktiveras så skickar cellerna ut molekyler som skapar den immunologiska 
överkänslighetsreaktionen. Bland de viktigaste molekylerna för denna typ av reaktion är 
histamin. Denna reaktion är ofta ganska omedelbar efter exponering. Ytterligare en fas av 
allergi inträffar senare, oftast flera timmar efter exponering. Första gången man träffar på ett 
allergen kommer inte kroppen svara med allergisk reaktion, utan först måste cellerna i 
kroppen ”lära upp” immunsvaret att känna igen allergenet. Denna process när ett allergiskt 
immunsvar mot allergenet uppstår kallas sensibilisering. Både den s.k. adaptiva delen av 
immunförsvaret som omfattar antikroppsproducerande celler och immunmodulerande T-
celler, och den medfödda (s.k. inat) delen är involverade i sensibiliseringen och avgörande för 
om allergi uppstår.  
För att diagnostisera patienter är patientens historia central för korrekt diagnos. Men även 
immunologiska tester genomförs, som att mäta förekomst i blod av IgE mot olika 
allergenkällor. Vanligt förekommande är också så kallat prick-test, då en liten droppe av 
allergenextrakt appliceras på huden och så punkteras huden, och storleken på 
rodnaden/svullnaden mäts. Extrakten som används för att diagnostisera pälsdjursallergi är 
oftast baserade på päls eller hud från allergenkällan. Dessa extrakt har visat sig variera när det 
gäller allergeninnehåll.  
För att undvika allergiska symtom kan man reducera exponering mot källan man blir 
allergisk mot, men då krävs korrekt diagnos. Övriga behandlingar är symptomatisk 
behandling, så som anti-inflammatoriska läkemedel och antihistaminer. Utöver det finns det 
ett biologiskt läkemedel, en antikropp som binder IgE, detta läkemedel ges via injektion. Den 
enda behandlingen är botande är dock immunterapi, där man traditionellt injicerar små doser 
av allergenextrakt i ökande mängder så att kroppen tolererar eller byter typ av immunsvar 
mot allergenet. Exakt vad som är mekanismen bakom denna omprogrammering av 
immunsvaret är inte helt klarlagt. Denna behandling medför risk att patienten drabbas av 
systemisk reaktion, med bieffekter som kan vara direkt farliga. Därför utförs denna 
behandling på sjukhus, kräver försiktig uppdosering och lång behandling med många 
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injektioner. Immunterapin för allergi använder sig i vissa fall av en hjälpsubstans för att ge ett 
starkare och bättre immunsvar, dessa ämnen kallas adjuvans. Immunterapi mot allergi skulle 
kunna förbättras om bättre adjuvans fanns tillgängligt, både när det gäller säkerhet och 
effektivitet.  
Syftet med denna avhandling är att förbättra kunskapen kring allergenkällor och enskilda 
allergen komponenter som patienter med allergi mot hund eller häst reagerar mot. Detta för 
att öka möjligheterna till korrekt diagnos och behandling. Vidare utvärderas ett nytt adjuvans 
med potential att förbättra effekten av immunterapi för att bota allergi. 
I delarbete I av avhandling undersöks hundsaliv som källa för hundallergener, och hur 
saliven kan bidra till att ge korrekt diagnos av allergi mot hund. I dag är de extrakt som 
används baserade på hundmjäll, och det har påvisats att de varierar i hur mycket de innehåller 
i fråga om allergen. I studien så analyserades IgE nivåerna bland patienter med positivt 
blodprov mot hundmjäll, och jämfördes med IgE nivåerna mot salivextrakt. Även serum från 
individer med misstänkt allergi mot hund men med negativt serum-IgE-resultat mot 
hundmjällsextrakt inkluderades i studien. Dessa uppvisade också IgE mot salivextrakt.  
För att undersöka om saliv kan aktivera basofiler, togs ett blodprov från tre individer, varav 
två med hundallergidiagnos, samt en frisk frivillig. Från detta blodprov analyserades aktiva 
basofiler. Salivextraktet visades vara aktiverande för de tre testade individerna, men endast 
för två av individerna med hundmjällsextrakt. För att kunna identifiera möjliga allergener i 
hundsaliv så genomfördes en proteinseparation och masspektrometrianalys av IgE bindande-
salivproteiner. Fyra tidigare okända IgE bindande proteiner kunde identifieras. Dessa 
potentiella allergen kan vara intressanta att undersöka vidare. I den vetenskapliga litteraturen 
finns det inget stöd för att vissa hundraser skulle tålas bättre av allergiker, men det hävdas 
ibland i andra sammanhang att vissa raser är hypoallergena, d.v.s. allergiker tål dem bättre. 
För att undersöka om hundar kan uppvisa olika profil av allergen, så gjordes en 
sammanslagning jämfördes saliv insamlat från enskilda hundar tillhörande olika raser och 
kön med avseende på IgE-bindande proteiner. En stor variation i det individuella mönstret av 
IgE bindande proteiner hos hundarna kunde påvisas. 
 Allergi mot häst är det som undersöks i delarbete II. Allergi mot häst är förhållandevis 
vanligt, även bland grupper som inte har någon uppenbar kontakt med hästar. Idag finns fyra 
kända allergen från häst rapporterade, och dessa benämns Equ c 1 till 4 efter det latinska 
namnet för häst, Equus caballus, och numret efter vilken ordning de upptäckts i. Men i den 
vetenskapliga litteraturen spekuleras det i om det kan finnas flera okända allergener. 
Hypotesen i denna studie var att det finns flera okända allergen som bidrar till allergi mot 
häst. Ett tidigare inte rapporterat hästprotein visade sig binda IgE när vi undersökte extrakt 
som används diagnostiskt, och detta identifierades som ett protein med snarlik sekvens till ett 
känt allergen från ko. Ytterligare ett protein identifierades som visade sig ha likheter med ett 
vanligt allergen hos katt. Slutligen så identifierades hela molekylen för ett tidigare rapporterat 
allergen från häst (Equ c 2), men där bara delar av allergenet tidigare varit kända. Samtliga 
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dessa tre nya allergen producerades i ett baktieriesystem för att möjliggöra analys av IgE-
reaktivitet. Dessutom framställdes de tre allergenen Equ c 1, 3 och 4 så att vi kunde jämföra 
de potentiella nya allergenens betydelse med tidigare kända hästallergen. 
Vi undersökte IgE-bindning med en analysmetod som möjliggjorde att vi kunde fastställa 
mängd IgE i serum med hjälp av en standard. 100 sera från individer med IgE mot 
hästmjällsextrakt samlades in och deras mängd IgE mot alla de sex allergenkomponenterna 
analyserades. Alla sera hade IgE mot ett eller flera av komponenterna, och minst 36 % av alla 
sera hade IgE mot ett av de nyidentifierade allergenerna.  
I delarbete III undersöktes en ny kitosanbaserad partikulär hydrogel som föreslagits ha 
immunstimulerande förmåga. Kitosan är en sockerpolymer som tillverkas från kitin, en i 
naturen vanlig byggsten i olika typer av skelett, t.ex. räkskal. Kitosan kan kemiskt bearbetas 
till en gel bestående av 1 % polymer och i övrigt vatten. Gelen, som tillverkas under namnet 
ViscoGel, kan vidare fördelas till partiklar av bestämd storlek. 
Det första som undersöktes var effekten av ViscoGel på humana s.k. antigenpresenterande 
celler. Denna typ av celler har en centralbetydelse vid aktiveringen av ett immunsvar. 
Cellerna odlades upp och deras förmåga att ta upp hydroelastiska partiklar, vars storlek i 
denna studie var 10 eller 200 µm, studerades. För denna analys färgades partiklarna in med 
en färg och undersöktes med mikroskopi och kvantitativt med flödescytometri. Positiva 
celler, d.v.s. med färg inuti, kunde detekteras för båda partikelstorlekarna med båda 
metoderna. Aktivering av dessa celler undersöktes också, efter att de odlats i närvaro av 
ViscoGel. En uppreglering av två centrala molekylär inom immunaktivering kunde 
detekteras, vilket gör detta partikulära kitosan immunologiskt relevant att fortsätta att 
undersöka. 
I delarbete IV beskrivs en randomiserad klinisk prövning av ViscoGel. Detta var en fas I/IIa 
studie som undersökte säkerhet och effekt av ViscoGel som adjuvans. I den första delen fick 
30 friska frivilliga ViscoGel injicerat i muskel. Säkerhet och bieffekter undersöktes för tre 
ViscoGel doser för att kunna välja en lämplig dos för effektdelen av studien. Ingen patient 
visade någon allvarlig bieffekt. Efter att dosen valts, så injicerades ViscoGel tillsammans 
med ett redan beprövat vaccin, Act-HIB, som skyddar mot en bakterieorsakad meningit. För 
att undersöka effekten så lottades de friska frivilliga till en av fem grupper, en grupp med 
endast normaldos av modellvaccinet och två grupper med olika mindre mängd vaccin, och 
två grupper som fick samma doser av vaccinet tillsammans med ViscoGel. För att utvärdera 
om ViscoGel har förmåga att stimulera immunsvaret mot Act-HIB, d.v.s. verka som ett 
adjuvans, togs blodprov innan och vid fem tillfällen efter injektionen, och antikroppsnivåerna 
mot vaccinet analyserades. Ingen skillnad kunde detekteras mellan korresponderande 
vaccinmängd och vaccinmängd i kombination med ViscoGel. Vid vaccination eftersträvas 
inte bara ett antikroppsvar utan även ett cellulärt svar. Celler från ett blodprov taget innan och 
sju dagar efter injektionen undersöktes, och en markant reducering av det cellulära svaret, 
analyserat med avseende på IFN - utsöndring, kunde detekteras bland de individer som inte 
fått ViscoGel, medan ViscoGel kunde förhindra en reduktion av ett cellulärt immunsvar efter 
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vaccinering. Sammantaget så tålde deltagarna ViscoGel bra och även om det primära 
effektmålet inte uppnåddes så är de immunologiska effekterna är av intresse att fortsätta 
undersöka. 
Sammanfattningsvis: 
I delarbete I så visar vi att hundsaliv är en allergenkälla, och att exponering av hundsaliv 
bland personer med allergi mot hund kan orsaka reaktion. I Delarbete II så identifierades 3 
tidigare okända molekyler från häst som kan orsaka allergisk reaktion, vilket kan förbättra 
diagnostiska möjligheter. I delarbete III så undersökte vi att kitosanbaserade partiklar kunde 
tas upp av immunologiska celler samt aktivera dessa, vilket gör dessa partiklar av intresse för 
att förbättra vaccin. Slutligen så kunde vi visa i delarbete IV att dessa kitosanpartiklar inte 
orsakade oönskade bieffekter, och kan anses vara säkert att kombinera med vaccin. 
To summarize the results from this thesis:  
From Paper I, dog saliva is a source of allergen, and exposure might lead to allergic 
reactions among dog allergic patients. In Paper II, we identified molecules from horse that 
can cause allergic reaction, that was previously unknown, possible improve diagnostic 
methods. In paper III, we could conclude that chitosan based particles are taken up by 
human immunological cells and activate them, making this compound interesting for 
boosting vaccines. In paper IV, we could conclude that the chitosan based particles can be 
considered safe when injected in healthy subjects in combination with vaccine. 
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